MX2024004242A - Agentes de union multiespecificos contra pd-l1 y cd137 en terapia combinada. - Google Patents
Agentes de union multiespecificos contra pd-l1 y cd137 en terapia combinada.Info
- Publication number
- MX2024004242A MX2024004242A MX2024004242A MX2024004242A MX2024004242A MX 2024004242 A MX2024004242 A MX 2024004242A MX 2024004242 A MX2024004242 A MX 2024004242A MX 2024004242 A MX2024004242 A MX 2024004242A MX 2024004242 A MX2024004242 A MX 2024004242A
- Authority
- MX
- Mexico
- Prior art keywords
- binding agents
- combined therapy
- agents against
- multispecific binding
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253106P | 2021-10-06 | 2021-10-06 | |
| US202163257901P | 2021-10-20 | 2021-10-20 | |
| PCT/EP2022/077749 WO2023057535A1 (en) | 2021-10-06 | 2022-10-05 | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004242A true MX2024004242A (es) | 2024-07-29 |
Family
ID=84286302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004242A MX2024004242A (es) | 2021-10-06 | 2022-10-05 | Agentes de union multiespecificos contra pd-l1 y cd137 en terapia combinada. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240409653A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412714A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538755A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240082387A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119053340A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022360108A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233512A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311901A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004242A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023057535A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025242827A1 (en) * | 2024-05-22 | 2025-11-27 | Genmab A/S | Bispecific antibody against pd-l1 and cd137 in combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CN106459165B (zh) | 2014-04-01 | 2021-04-20 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| AU2017272721B2 (en) | 2016-05-30 | 2023-03-30 | Astellas Pharma Inc. | Novel genetically engineered vaccinia viruses |
| US20190185571A1 (en) | 2016-07-28 | 2019-06-20 | Musc Foundation For Research Development | Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors |
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| BR112021026309A2 (pt) * | 2019-06-26 | 2022-06-07 | Ap Biosciences Inc | Anticorpos para ativação de células t |
| WO2021156326A1 (en) * | 2020-02-04 | 2021-08-12 | Genmab A/S | Antibodies for use in therapy |
| WO2022148410A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备 |
-
2022
- 2022-10-05 AU AU2022360108A patent/AU2022360108A1/en active Pending
- 2022-10-05 IL IL311901A patent/IL311901A/en unknown
- 2022-10-05 US US18/698,354 patent/US20240409653A1/en active Pending
- 2022-10-05 CA CA3233512A patent/CA3233512A1/en active Pending
- 2022-10-05 EP EP22801732.3A patent/EP4412714A1/en active Pending
- 2022-10-05 WO PCT/EP2022/077749 patent/WO2023057535A1/en not_active Ceased
- 2022-10-05 CN CN202280079918.2A patent/CN119053340A/zh active Pending
- 2022-10-05 MX MX2024004242A patent/MX2024004242A/es unknown
- 2022-10-05 KR KR1020247014273A patent/KR20240082387A/ko active Pending
- 2022-10-05 JP JP2024521343A patent/JP2024538755A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119053340A (zh) | 2024-11-29 |
| EP4412714A1 (en) | 2024-08-14 |
| AU2022360108A1 (en) | 2024-05-02 |
| WO2023057535A1 (en) | 2023-04-13 |
| CA3233512A1 (en) | 2023-04-13 |
| IL311901A (en) | 2024-06-01 |
| KR20240082387A (ko) | 2024-06-10 |
| US20240409653A1 (en) | 2024-12-12 |
| JP2024538755A (ja) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001353A1 (es) | Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2. | |
| CL2024001607A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| BR112018071023A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose | |
| MX2024000674A (es) | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2025003354A (es) | Anticuerpos que se unen a 5t4 | |
| BR112017007817A2 (pt) | tratamento do câncer com estimuladores imunológicos | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
| BR112018071031A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr | |
| MX2022001249A (es) | Tratamiento de tumores evasivos inmunitarios. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| CL2022002093A1 (es) | Anticuerpos para usar en terapia. | |
| BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
| BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2017011237A (es) | Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides. | |
| MX2024012368A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2023006404A (es) | Terapia combinada de anticuerpos y taxanos. | |
| MX2024003563A (es) | Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa. |